SCHEMBL697012

SCHEMBL697012

[CH2]COC(=O)OCC1CC1

nearest known ligand 0.37

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.37
SLC1A3 P43003 2/20 0.33
SLC1A2 P43004 2/20 0.33
SLC1A1 P43005 2/20 0.33
PTGIR P43119 2/20 0.32
PTGDR Q13258 1/20 0.32
PARP15 Q460N3 1/20 0.32
PARP10 Q53GL7 1/20 0.32
PARP2 Q9UGN5 1/20 0.32
ALOX5 P09917 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL704782 0.91 LMNA (0.47) LMNASLC1A3SLC1A2SLC1A1PARP15
SCHEMBL697773 0.91 LMNA (0.43) LMNASLC1A3SLC1A2SLC1A1PARP15
SCHEMBL696997 0.90 LMNA (0.50) LMNASLC1A3SLC1A2SLC1A1PARP15
SCHEMBL1444506 0.88 LMNA (0.43) LMNASLC1A3SLC1A2SLC1A1PTGIR
SCHEMBL23129641 0.79 LMNA (0.57) LMNASLC1A3SLC1A2SLC1A1PARP15
SCHEMBL8275334 0.79 LMNA (0.38) LMNASLC1A3SLC1A2SLC1A1PTGIR
SCHEMBL698071 0.79
SCHEMBL12446343 0.79 LMNA (0.38) LMNASLC1A3SLC1A2SLC1A1PTGIR
SCHEMBL696905 0.78 EPHX1 (0.31)
SCHEMBL1672623 0.78 LMNA (0.55) LMNASLC1A3SLC1A2SLC1A1PARP15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423199-A1 Substituted imidazoles and their use as pesticides Pfizer Limited (GB) 2012-02-29 EP disclosed
EP-2320732-A2 SUBSTITUTED IMIDAZOLE COMBINATIONS Pfizer Inc. (US) 2011-05-18 EP disclosed
EP-1981853-B1 SUBSTITUTED IMIDAZOLES AND THEIR USE AS PESTICIDES PFIZER LTD (GB) 2011-04-13 EP disclosed
US-7825149-B2 Substituted imidazoles PFIZER LIMITED (GB) 2010-11-02 US disclosed
WO-2010020896-A2 SUBSTITUTED IMIDAZOLE COMBINATIONS PFIZER INC. (US) 2010-02-25 WO disclosed
US-20100041712-A1 SUBSTITUTED IMIDAZOLE COMBINATIONS PFIZER INC. (US) 2010-02-18 US disclosed
US-20090312326-A1 SUBSTITUTED IMIDAZOLES PFIZER LIMITED (GB) 2009-12-17 US disclosed
US-7592362-B2 Substituted imidazoles PFIZER LIMITED (GB) 2009-09-22 US disclosed
US-7547718-B2 Substituted imidazoles PFIZER LIMITED (GB) 2009-06-16 US disclosed
US-7544706-B2 Substituted imidazoles PFIZER LIMITED (GB) 2009-06-09 US disclosed
EP-1981853-A1 SUBSTITUTED IMIDAZOLES AND THEIR USE AS PESTICIDES Pfizer Limited (GB) 2008-10-22 EP disclosed
US-20080125473-A1 SUBSTITUTED IMIDAZOLES PFIZER LIMITED (GB) 2008-05-29 US disclosed
US-20080119536-A1 SUBSTITUTED IMIDAZOLES PFIZER LIMITED (GB) 2008-05-22 US disclosed
WO-2007083207-A1 SUBSTITUTED IMIDAZOLES AND THEIR USE AS PESTICIDES PFIZER LIMITED (GB) 2007-07-26 WO disclosed
US-20070167506-A1 SUBSTITUTED IMIDAZOLES PFIZER INC. (US) 2007-07-19 US disclosed
EP-1471901-A1 SPERMIDINE DERIVATIVES FOR THE TREATMENT OF CHRONIC NEURODEGENERATIVE DISEASES UNIVERSITY OF SOUTHAMPTON (GB) 2004-11-03 EP disclosed
WO-2003066037-A1 SPERMIDINE DERIVATIVES FOR THE TREATMENT OF CHRONIC NEURODEGENERATIVE DISEASES UNIVERSITY OF SOUTHAMPTON (GB) 2003-08-14 WO disclosed
EP-0200692-B1 ANDROSTANE-17-BETA-CARBOXYLIC-ACID ESTERS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOUND CONTAINING THEM Aktiebolaget Draco (SE) 1991-09-11 EP disclosed
US-4804656-A ANTIINFLAMMATORY AGENTS AKTIEBOLAGET DRACO (SE) 1989-02-14 US disclosed
EP-0200692-A1 Androstane-17-beta-carboxylic-acid esters, process for their preparation and pharmaceutical compound containing them Aktiebolaget Draco (SE) 1986-11-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125473-A1 SUBSTITUTED IMIDAZOLES ABL1, TYR, CYP3A4 LMNA 3030/4885SLC1A3 1804/4885SLC1A2 2128/4885
US-20090312326-A1 SUBSTITUTED IMIDAZOLES ABL1, TYR, CYP3A4 LMNA 3030/4885SLC1A3 1804/4885SLC1A2 2128/4885
US-20070167506-A1 SUBSTITUTED IMIDAZOLES ABL1, TYR, CYP3A4 LMNA 3030/4885SLC1A3 1804/4885SLC1A2 2128/4885
US-20080119536-A1 SUBSTITUTED IMIDAZOLES ABL1, TYR, CYP3A4 LMNA 3030/4885SLC1A3 1804/4885SLC1A2 2128/4885
US-20100041712-A1 SUBSTITUTED IMIDAZOLE COMBINATIONS ING2, IGFBP2, IGFBP1 LMNA 4361/4885SLC1A3 2809/4885SLC1A2 3278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.